Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6950716 | 1.00 | HMGCR (0.61) | HMGCR | |
| SCHEMBL6950755 | 0.90 | HMGCR (0.59) | HMGCR | |
| SCHEMBL9441641 | 0.90 | HMGCR (0.59) | HMGCR | |
| SCHEMBL6944885 | 0.84 | HMGCR (0.42) | HMGCR | |
| SCHEMBL6944896 | 0.84 | HMGCR (0.42) | HMGCR | |
| SCHEMBL10636920 | 0.83 | HMGCR (0.84) | HMGCR | |
| SCHEMBL6950792 | 0.83 | HMGCR (0.51) | HMGCR | |
| SCHEMBL6950784 | 0.83 | HMGCR (0.51) | HMGCR | |
| SCHEMBL9702787 | 0.83 | HMGCR (0.59) | HMGCR | |
| SCHEMBL9441493 | 0.80 | HMGCR (0.61) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630502-B2 | Administering combination of a cholesterol lowering drug and an angiotensin converting enzyme inhibitor for therapy of atherosclerosis | E.R. SQUIBB & SONS, INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030149101-A1 | METHOD FOR PREVENTING, STABILIZING OR CAUSING REGRESSION OF ATHEROSCLEROSIS EMPLOYING A COMBINATION OF A CHOLESTEROL LOWERING DRUG AND AN ACE INHIBITOR | E. R. SQUIBB & SONS, INC., A CORP. OF DE | 2003-08-07 | — | — | US | disclosed |
| EP-0738512-B1 | Use of a HMG CoA reductase inhibitor to prevent a second heart attack | BRISTOL MYERS SQUIBB CO (US) | 2003-07-02 | — | — | EP | disclosed |
| US-5593971-A | ALONE OR IN COMBINAATION WITH ANGIOTENSIN CONVERTING ENZYME INHIBITOR | E. R. SQUIBB & SONS, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0738512-A1 | Use of a HMG CoA reductase inhibitor to prevent a second heart attack | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-23 | — | — | EP | disclosed |
| EP-0457514-B1 | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | SQUIBB & SONS INC (US) | 1996-08-21 | — | — | EP | disclosed |
| US-5461039-A | Administering squalene synthetase inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1995-10-24 | — | — | US | disclosed |
| US-5349069-A | Process for the preparation of 4-phosphinyl-3-keto-carboxylate and 4-phosphonyl-3-keto-carboxylate intermediates useful in the preparation of phosphorus containing HMG-COA reductase inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1994-09-20 | — | — | US | disclosed |
| US-5298497-A | Enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1994-03-29 | — | — | US | disclosed |
| US-5298625-A | Process for the preparation of 4-phosphinyl-3-keto-carboxylate and 4-phosphonyl-3-keto-carboxylate intermediates useful in the preparation of phosphorus containing HMG-CoA reductase inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1994-03-29 | — | — | US | disclosed |
| US-H1286-H | Administering an anticholesterol agents which is an enzyme inhibitor of angiotensin converting enzyme or/and squalene synthetase | E. R. SQUIBB & SONS, INC. (US) | 1994-02-01 | — | — | US | disclosed |
| US-5276021-A | Anticholesterol or antilipemic agents | E. R. SQUIBB & SONS, INC. (US) | 1994-01-04 | — | — | US | disclosed |
| US-5274155-A | Intramolecular arbuzov process for the preparation of intermediates useful in the preparation of phosphorus containing HMG-COA reductase inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1993-12-28 | — | — | US | disclosed |
| US-5190970-A | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1993-03-02 | — | — | US | disclosed |
| EP-0508665-A2 | Use of ACE inhibitors for lowering serum cholesterol | E.R. SQUIBB & SONS, INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0482498-A2 | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1992-04-29 | — | — | EP | disclosed |
| EP-0461548-A2 | Method for preventing a second heart attack employing and HMG CoA reductase inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1991-12-18 | — | — | EP | disclosed |
| EP-0457514-A1 | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1991-11-21 | — | — | EP | disclosed |
| EP-0401705-A2 | Use of an HMG CoA reductase inhibitor and/or a squalene synthetase inhibitor for treating peripheral atherosclerotic disease | E.R. Squibb & Sons, Inc. (US) | 1990-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149101-A1 | METHOD FOR PREVENTING, STABILIZING OR CAUSING REGRESSION OF ATHEROSCLEROSIS EMPLOYING A COMBINATION OF A CHOLESTEROL LOWERING DRUG AND AN ACE INHIBITOR | HMGCR, ACE, APOB | HMGCR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.